A Leader Redefining How Kidney Disease is Treated
XRx-101, a possible antiviral treatment solution to combat the effects of Coronavirus / COVID-19
XRx-008, a late stage drug development program targeting uric acid lowering for Autosomal Dominant Polycystic Kidney Disease
XRx-221, a co-development program to treat Diabetic Nephropathy
XORTX Therapeutics Inc. is a biopharmaceutical company with three clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic Nephropathy (T2DN). The Company has strong intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.
Press Releases
XORTX Grants Options
CALGARY, Alberta, Jan. 12, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has granted in accordance with the Company’s stock option plan an aggregate of 700,000 options ...
Read More
Read More